VSTA Stock UPDATES Vistagen Therapeutic (VSTA) 0.6000 08/11/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Vistagen Therapeutic (VSTA) 0.6000 $VSTA

VistaGen Therapeutics, Inc. - Product Pipeline Review - 2014
M2 - Fri Jul 25, 3:32AM CDT
Summary

VistaGen Therapeutics, Inc. (VSTA) - Product Pipeline Analysis
M2 - Fri Jul 11, 3:24AM CDT
Summary

VistaGen Receives Notice of Allowance for Canadian Patent Expanding Stem Cell Technology Platform
Marketwire - Mon Jun 16, 8:30AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue and regenerative medicine, today announces that the Canadian Intellectual Property Office has issued a Notice of Allowance for Canadian patent No. 2,684,022, entitled "Mesoderm and Definitive Endoderm Cell Populations." This patent, which is licensed exclusively to VistaGen by the Icahn School of Medicine at Mount Sinai in New York, will expand VistaGen's intellectual property portfolio for pluripotent stem cell culture systems that produce human cells of the endoderm lineage, including liver, lung, pancreas, parathyroid and thyroid cells.

Global Stem Cell Market Report 2013
M2 - Tue Dec 17, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/qsfq7f/stem_cell_markets) has announced the addition of the "Global Stem Cell Market Report 2013" report to their offering. Traditionally, stem cells have been classified as either embryonic, adult (tissue-specific or cord blood) stem cells. However, recent understanding of stem cell biology may provide new approaches for the treatment of a number of diseases as well as tissue/organ injuries, including cardiovascular disease, neurological disease, musculoskeletal disease, diabetes and hematopoietic disorders. Stem cell fate is determined by both intrinsic regulators and the extra-cellular environment (niche), and their expansion and differentiation ex vivo are generally controlled by growing them in a specific configuration (monolayer or three-dimensional culture). This process, which is vital to enable stem cells to be used for therapeutic purposes, is called differentiation. Differentiation is a process involving unspecialized cells progressing to become specialized cells with restricted developmental potential. "Global Stem Cell Market Report 2013", describes the specific market segments of the medical research space using stem cells for research and development (R&D) purposes. This study reviews all of the generally accepted analytical methods that are currently in use today for preparing and using stem cells. Key Topics Covered: 1. Overview 2. Biology of Stem Cells 3. Stem Cell Therapy 4. Market Analysis of the Stem Cell Space 5. Strategic Roadmap to Cell Therapy Industry 6. Funding for Regenerative Medicine Research 7. Current Stem Cell Research 8. Company Profiles Companies Mentioned: - Athersys, Inc - Brainstorm Cell Therapeutics, Inc - CryoLife, Inc - Epistem PLC - Forticell Bioscience, Inc - Glycosan Biosystems, Inc - Humacyte, Inc - International Stem Cell Corporation - Japan Tissue Engineering Co., Ltd - LifebankUSA - Miltenyi Biotec - Novocell, Inc - Osiris Therapeutics, Inc - Pluristem Therapeutics, Inc - ReNeuron Group Plc - Stempeutics Research Private Limited - Tengion, Inc - VistaGen Therapeutics, Inc - ZenBio, Inc For more information visit http://www.researchandmarkets.com/research/qs...ll_markets

OTC Signal Daily Stock Watch - VistaGen (OTCQB: VSTA)
WorldStockWire - Mon Sep 09, 1:00AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com

Lymphoma - Pipeline Review, H2 2013 Reveals the Latest News and Deals Relating to the Products
M2 - Wed Sep 04, 9:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/37s3zw/lymphoma) has announced the addition of the "Lymphoma - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lymphoma. Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Lymphoma. - A review of the Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lymphoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. Some of the Companies Mentioned: - Bristol-Myers Squibb Company - Genzyme Corporation - Biogen Idec Inc. - Allergan, Inc. - Shionogi & Co., Ltd. - Sanofi-Aventis - AstraZeneca PLC - Quark Pharmaceuticals, Inc. - Daiichi Sankyo Company, Ltd - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Sangamo BioSciences, Inc. - XenoPort, Inc. - BioLineRx, Ltd. - LEO Pharma A/S - Pfizer Inc. - Sun Pharmaceutical Industries Limited - VistaGen Therapeutics , Inc. - Palau Pharma S.A - Snowdon Inc. - Neurotune AG - AngioChem Inc. - PharmEste - Trevena, Inc. - MediProPharma, Inc. - Celtic Pharmaceutical Holdings L.P. - Vichem Chemie Research Ltd. - RaQualia Pharma Inc. - Naurex, Inc. - Cytogel Pharma, LLC For more information visit http://www.researchandmarkets.com/research/37s3zw/lymphoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

VistaGen Provides Update on $36 Million Strategic Financing Agreement
Marketwire - Fri Jun 28, 11:13AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announced an update on the status of its strategic financing agreement with Autilion AG.

VistaGen Therapeutics Presents CardioSafe 3D(TM) and LiverSafe 3D(TM) Developments at International Society of Stem Cell Research's 11th Annual Meeting
Marketwire - Mon Jun 17, 9:29AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, presented key developments involving its CardioSafe 3D(TM) and LiverSafe 3D(TM) bioassay systems in poster presentations at the 11th Annual Meeting of the International Society of Stem Cell Research (ISSCR), the largest forum for stem cell and regenerative medicine professionals from around the world, held June 12 to 15, 2013, in Boston, Massachusetts.

VistaGen Therapeutics and Duke University Publish Results on Production of Functional 3D Human Heart Tissue
Marketwire - Tue May 07, 7:00AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, announced that its high-quality, human pluripotent stem cell-derived cardiomyocytes (heart cells) were used by collaboration partner Duke University to grow a revolutionary three-dimensional (3D) human heart muscle. An abstract of the original research article published in Biomaterials, an international journal covering the science and clinical application of biomaterials, can be found online at: http://www.sciencedirect.com/science/article/...1213004705.

VistaGen Therapeutics Inc signs USD36m strategic financing agreement with Bergamo Acquisition Corp's European subsidiary
M2 - Thu Apr 11, 9:41AM CDT
Biotechnology company VistaGen Therapeutics Inc (OTCQB:VSTA) said on Wednesday that it has entered into a USD36m strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp (OTC: BGMO), an investment holding company.

UPDATE: VistaGen Announces $36 Million Strategic Financing Agreement
Marketwire - Wed Apr 10, 12:25PM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces the signing of a strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp. (OTC: BGMO), a global diversified investment holding company.

VistaGen Announces $36 Million Strategic Financing Agreement
Marketwire - Wed Apr 10, 7:50AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces the signing of a strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp. (PINKSHEETS: BGMO), a global diversified investment holding company.

VistaGen Therapeutics to Present Enhancements and Expanded Validation of LiverSafe 3D(TM) at Society of Toxicology's 52nd Annual Meeting
Marketwire - Tue Mar 12, 10:08AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces that it will present key enhancements to LiverSafe 3D(TM), its human liver cell-based bioassay system designed to predict liver toxicity and drug metabolism issues, in a poster presentation at the Society of Toxicology's 52nd Annual Meeting, the world's premier toxicology conference, in San Antonio, Texas, on March 12, 2013, at 11:00 am PDT.

VistaGen Therapeutics to Present CardioSafe 3D(TM) Developments at Society of Toxicology's 52nd Annual Meeting
Marketwire - Mon Mar 11, 9:00AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces it will feature key developments involving CardioSafe 3D(TM), its pluripotent stem cell-based bioassay system for heart toxicity, in a poster presentation at the Society of Toxicology's 52nd Annual Meeting, the world's premier toxicology conference, in San Antonio, Texas, on March 11, 2013, at 7:30 am PDT.

VistaGen Therapeutics Enters Strategic Collaboration With Celsis to Further Advance LiverSafe 3D(TM)
Marketwire - Mon Mar 04, 8:02AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, and Celsis In Vitro Technologies ("Celsis" , the premier global provider of specialized in vitro products for drug metabolism, drug-drug interaction and toxicity screening, have entered into a new strategic collaboration agreement. The comprehensive goal of the agreement is to characterize and functionally benchmark VistaGen's human liver cell platform, LiverSafe 3D(TM), for studying and predicting human liver drug metabolism.

VistaGen's Collaborators Identify Definitive Precursor for Adult Blood and the Immune System
Marketwire - Thu Feb 07, 9:07AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announced significant advancements in its stem cell technology licensed from the University Health Network (UHN) in Toronto, Canada. The advancements, which improve VistaGen's ability to develop new stem cell-based bioassay systems and potentially improved cell therapies for human blood system disorders, were reported in the December 2012 edition of Cell Reports, an open-access journal from Cell Press.

Vistagen Therapeutics Successfully Completes Final Phase 1 Safety Study of AV-101
Marketwire - Wed Jan 23, 7:30AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today announced the successful completion of its final Phase 1 safety study of AV-101, a novel orally available prodrug candidate being developed for treatment of multiple conditions involving chronic neuropathic pain. The study results indicate that AV-101 is safe and well tolerated, with favorable bioavailability and pharmacokinetics.

VistaGen Therapeutics to Present at Noble Financial Capital Markets Ninth Annual Equity Conference
Marketwire - Tue Jan 22, 5:00AM CST
VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today announced that Shawn K. Singh, CEO of VistaGen, will present at Noble Financial Capital Markets' Ninth Annual Equity Conference.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 100

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading
SecureSpace Plants a Fifth Flag in Miami Beach Storage

Updated Category News Views 90

A small box on Alton Road may carry outsized weight Miami Beach does not hand out cheap, easy real estate wins, which is why SecureSpace's opening at 633 Alton Road deserves a closer look than its modest footprint might suggest. The newly rebranded SecureSpace Miami Beach facility has 18,358 square feet of traditional storage and locker space spread across 536 units, plus...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 102

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 88

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 101

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 112

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 257

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
MassMedia's Two PRSA Wins Put Campaign Strategy in Focus

Updated Category News Views 100

A pair of trophies is nice; the underlying work matters more. MassMedia picked up two honors at the 2026 PRSA Las Vegas Valley Chapter Pinnacle Awards, presented October 28 at Siena Golf Club. One was a Pinnacle Award in Community Relations for its Safe Teen Driving work with Sam & Ash Injury Law. The other was an Award of Excellence in Reputation and Brand Management for...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 186

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading

Top 5 Most Recently Viewed Articles

La-Z-Boy Faces Major Stock Decline After Weak Earnings Report

Updated Category News Views 264

La-Z-Boy Stock Experiences Significant Drop La-Z-Boy Incorporated (NYSE: LZB) witnessed a dramatic 23.55% decline in after-hours trading, with shares plummeting from $39.11 to $29.90. This downturn followed the release of disappointing first-quarter results that did not meet analysts' expectations, prompting concerns about operational challenges. Disappointing Earnings...

Continue Reading
CLEAR Secure, Inc. Reveals Impressive Q3 2025 Performance

Updated Category News Views 224

CLEAR Secure, Inc.'s Q3 2025 Financial Overview CLEAR Secure, Inc. (NYSE: YOU), the leader in secure identity technologies, has recently unveiled its financial highlights for the third quarter of the 2025 fiscal year. As an innovative firm at the forefront of identity verification, CLEAR continues to address the growing needs in the security sector amid increasing cyber...

Continue Reading
Ameren Corporation Celebrates 10 Years of Disability Inclusion

Updated Category News Views 62

Ameren Corporation Champions Disability Inclusion Ameren Corporation (NYSE: AEE) has made impressive advancements in promoting disability inclusion, scoring a perfect 100 on the Disability Equality Index for the tenth year running. This recognition highlights Ameren’s role as a leader in fostering an inclusive workplace that values diversity and actively supports...

Continue Reading
Labcorp Faces Lawsuit: Wiretapping Accusations Surface

Updated Category News Views 60

Labcorp's Legal Tangle Unveiled One minute you're on Labcorp's website searching for medical info, the next you're caught up in a class-action legal whirlwind. Legal drama is not on any patient’s checklist, but here we are, with Labcorp knee-deep in some serious allegations. The crux of the matter points to alleged wiretapping violations, with claims that Labcorp,...

Continue Reading
Advent's $2.5 Billion Acquisition of Sapiens: A New Era Looms

Updated Category News Views 203

Advent to Acquire Sapiens for $2.5 Billion Sapiens International Corporation N.V. (NASDAQ: SPNS), a leader in software solutions for the insurance sector, has seen its stock price soar following the exciting announcement that it will be acquired by global private equity firm Advent. The all-cash acquisition deal is valued at approximately $2.5 billion, indicating a...

Continue Reading